SCHEMBL1203558

SCHEMBL1203558

COc1ccc(CN(C)c2ccc3ncc(C(=O)Nc4ccc(CC(=O)O)cc4)n3n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ CLK1 P49759 1/20 0.42
▸ PTGDR2 Q9Y5Y4 2/20 0.42
▸ NTRK1 P04629 1/20 0.40
▸ NTRK3 Q16288 1/20 0.40
▸ NTRK2 Q16620 1/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ NR3C1 P04150 1/20 0.39
▸ CXCR1 P25024 1/20 0.39
▸ CXCR2 P25025 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ DHODH Q02127 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202900 0.91 PPARD (0.46) KDM4EPOLBNTRK1NTRK3NTRK2
SCHEMBL1202379 0.84 NTRK1 (0.47) KDM4EPOLBCLK1NTRK1NTRK3
SCHEMBL1202473 0.83 KDM4E (0.51) KDM4EPOLBCLK1PTGDR2RAB9A
SCHEMBL1203239 0.82 FYN (0.51) KDM4EPOLBCLK1PTGDR2NTRK1
SCHEMBL1203271 0.80 KMT2A (0.48) POLBRAB9AALDH1A1NPC1MAPT
SCHEMBL1202454 0.80 CXCR1 (0.52) NTRK1NTRK3NTRK2ALDH1A1KCNH2
SCHEMBL1202165 0.80 CXCR1 (0.52) NTRK1NTRK3NTRK2KCNH2CXCR1
SCHEMBL1203816 0.80 CXCR1 (0.52) NTRK1NTRK3NTRK2KCNH2NR3C1
SCHEMBL1203079 0.76 KCNH2 (0.44) KDM4ENTRK1NTRK3NTRK2KCNH2
SCHEMBL1202234 0.76 KDM4E (0.47) KDM4EPOLBCLK1PTGDR2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 KDM4E 698/4885POLB 3471/4885CLK1 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback